Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Cited by (983)

Items 501–600 of 983

1. Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy
   Ea Maria Tønning Tønnesen, Magnus Stougaard, Peter Meldgaard, Johanne Lade‐Keller · 2022 · Journal of Clinical Pathology
2. ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer
   Wenbo Zou, Hao Wang, Dingguo Wu, Yunyang Wu, Kuiping Zhou, Yuan-Shu Lian, Gengyun Chang, Yuze Feng, Jifeng Liang, Gao Huang · 2023 · Frontiers in Endocrinology
3. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma
   Shuyang Li, Wei Wang, Huihan Yu, Siyu Zhang, Wenxu Bi, Suling Sun, Bo Hong, Zhiyou Fang, Xueran Chen · 2023 · BMC Cancer
4. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer
   Jianxin Chen, Qinhong Zheng, Junhui Wang, Xueli Zhang, Yingguo Lv · 2024 · Medicine
5. Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy
   Shanshan Li, Ting Yuan, Jing Yuan, Bo Zhu, Degao Chen · 2024 · Journal of Cancer Research and Clinical Oncology
6. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report
   Yong Tang, Yadan Li, Lei Zhang, Guihui Tong, Zhu’an Ou, Zhuocai Wang, Henghui Zhang, Guibin Qiao · 2020 · Thoracic Cancer
7. DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma
   Di-Di Yuan, Zehong Wei, Yicheng Wang, Fang Cheng, Yu-Jie Zeng, Li Yang, Shang Zhang, Jian-Bo Li, R. Tang · 2021 · Frontiers in Oncology
8. Ferroptosis Patterns Correlate with Immune Microenvironment Characterization in Gastric Cancer
   Xiaotao Jiang, Fan Liu, Peng Liu, Yanhua Yan, Shaoyang Lan, Kunhai Zhuang, Yufeng Liu, Kailin Jiang, Yuancheng Huang, Kechao Nie et al. · 2021 · International Journal of General Medicine
9. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
   Hao Zeng, Fan Tong, Yawen Bin, Ling Peng, Xuan Gao, Xuefeng Xia, Xin Yi, Xiaorong Dong · 2022 · Frontiers in Immunology
10. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy
    Pasquale Pisapia, Antonino Iaccarino, Caterina De Luca, Gennaro Acanfora, Claudio Bellevicine, Roberto Bianco, Bruno Daniele, Luisa Ciampi, Marco De Felice, Teresa Fabozzi et al. · 2022 · International Journal of Molecular Sciences
11. Tumor mutational burden and efficacy of chemotherapy in lung cancer
    Juan Song, Yu Yan, Cuicui Chen, Jiamin Li, Ning Ding, Nuo Xu, Hairong Bao, Xin Zhang, Qunying Hong, Jian Zhou et al. · 2022 · Clinical & Translational Oncology
12. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
    Jacqueline V. Aredo, Sukhmani Kaur Padda · 2018 · Current Treatment Options in Oncology
13. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
    Dan Zhao, Isa Mambetsariev, Haiqing Li, Chen Chen, Jeremy Fricke, Patricia Fann, Prakash Kulkarni, Yan Xing, Peter P. Lee, Andrea Bild et al. · 2020 · Lung Cancer
14. CITEseq analysis of non-small-cell lung cancer lesions reveals an axis of immune cell activation associated with tumor antigen load and TP53 mutations
    Andrew M. Leader, John A. Grout, Christie Chang, Barbara B. Maier, Alexandra Tabachnikova, Laura A. Walker, Alona Lansky, Jessica Le Bérichel, Naussica Malissen, Melanie Davila et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
15. Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
    Helei Hou, Yongjie Wang, Dantong Sun, Jingjuan Zhu, Man Jiang, Xuchen Zhang, Na Zhou, Chuantao Zhang, Tianjun Li, Xiaochun Zhang · 2022 · Investigational New Drugs
16. Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy
    Maritza Ramos-Ramírez, Enrique Caballé‐Perez, José Lucio-Lozada, Eunice Romero-Núñez, Cesar Castillo-Ruiz, Lorena Dorantes-Sánchez, Diana Flores‐Estrada, Gonzalo Recondo, Pedro Barrios‐Bernal, Luis Antonio Cabrera-Miranda et al. · 2025 · Cancer and Metastasis Reviews
17. A comprehensive analytical method ‘Regulatome’ revealed a novel pathway for aerenchyma formation under waterlogging in wheat
    Hao Gao, Mingjiong Chen, Nanfei Jin, Lingzhen Ye, Guoping Zhang, Qiufang Shen, Zhengyuan Xu · 2025 · Physiologia Plantarum
18. Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
    Shenao Fu, Jiayao Ma, Changjing Cai, Jun Tan, Xiangying Deng, Hong Shen, Shan Zeng, Yihong Chen, Ying Han · 2025 · Journal of Experimental & Clinical Cancer Research
19. Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study
    Hongbin Zhang, Yuan Wang, Qiaoxia Ji, Hongmei Cai, Xiangcun Liang, Jiong Xie, Hua Li, Jun Wang, Guiyun Zhu, Erpeng Tian et al. · 2021 · Oncology Letters
20. Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients
    Taohua Yue, Shuai Zuo, Jing Zhu, Shihao Guo, Zhihao Huang, Jichang Li, Xin Wang, Yucun Liu, Shanwen Chen, Pengyuan Wang · 2021 · Frontiers in Cell and Developmental Biology
21. Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy
    Javier Ramos‐Paradas, David Gómez-Sánchez, Aranzazú Rosado, Alvaro Conrado Ucero, Irene Ferrer, Ricardo García‐Luján, Jon Zugazagoitia, Nuria Carrizo, Ana B. Enguita, Esther Conde et al. · 2022 · Journal of Clinical Medicine
22. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy
    Xiang Dong, Zewu Zhang, Qin Zhang, Lu Chen, Guangtai Cao, Chen Liu, Tianqiang Song, Wei Lu, Wei Zhang · 2022 · Journal of Cancer Research and Clinical Oncology
23. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
    Wengang Zhang, Handai Xia, Rui Ryan Yang, Yuqing Zhang, Qi Zheng, Xiaoling Shang, Ni Liu, Xinchun Ma, Chenxi Wei, Hang Chen et al. · 2022 · Frontiers in Immunology
24. Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma
    Qinyang Wang, Ziyang Mao, Wenyuan Li, Shumei Wang, Lei Wang, Lin Chen, Zhe Yang, Xiaolan Fu, Panpan Jiang, Yixue Bai et al. · 2022 · Frontiers in Immunology
25. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
    Kenji Morimoto, Tadaaki Yamada, Ryo Sawada, Koichi Azuma, Yasuhiro Gotô, Taishi Harada, Shinsuke Shiotsu, Nobuyo Tamiya, Yusuke Chihara, Takayuki Takeda et al. · 2023 · Cancer Immunology Immunotherapy
26. The predictive value of plasma exosomal lncRNAs/mRNAs in NSCLC patients receiving immunotherapy
    Wang, Yue, Cao, Shuhui, Li, Jingwen, Zhang, Yao, Ling, Xuxinyi, Zhang, Lincheng, Zhou, Yan, Zhong, Hua · 2023 · Advances in Medical Sciences
27. Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients
    Sheehyun Kim, Sungjae Kim, Se Hyun Kim, Eun Hee Jung, Koung Jin Suh, Yu Jung Kim, Nak‐Jung Kwon, Hyojin Kim, Jin-Haeng Chung, Jong Seok Lee · 2023 · Translational Lung Cancer Research
28. Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
    Izabela Chmielewska, Paweł Adam Krawczyk, Anna Grenda, Magdalena Wójcik-Superczyńska, Natalia Krzyżanowska, Michał Gil, Janusz Milanowski · 2023 · Cancers
29. Construction of a genomic instability-derived predictive prognostic signature for non-small cell lung cancer patients
    Wei Li, Huaman Wu, Juan Xu · 2023 · Cancer Genetics
30. Heterogeneity in the Metastatic Microenvironment: JunB-Expressing Microglia Cells as Potential Drivers of Melanoma Brain Metastasis Progression
    Orit Adir, Orit Sagi‐Assif, Tsipi Meshel, Shlomit Ben‐Menachem, Metsada Pasmanik, Dave S.�B. Hoon, Isaac P. Witz, Sivan Izraely · 2023 · Cancers
31. Immunotherapy in oncogene addicted non-small cell lung cancer
    Luke S. McLean, José Luis Leal, Benjamin Solomon, Thomas John · 2021 · Translational Lung Cancer Research
32. Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer
    Li Qun Zhou, Litang Huang, Qiuli Xu, Yanling Lv, Zimu Wang, Ping Zhan, Hedong Han, Yang Washington Shao, Dang Lin, Tangfeng Lv et al. · 2021 · Frontiers in Oncology
33. A promising prognostic signature for lung adenocarcinoma (LUAD) patients basing on 6 hypoxia-related genes
    Jie Luo, Xiaotian Du · 2021 · Medicine
34. Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients
    Imke B. Bruns, Joost B. Beltman · 2022 · Scientific Reports
35. Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
    Liyuan Gao, Weizhang Shen · 2022 · Frontiers in Genetics
36. Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
    Giuseppe Bronte, Donato Michele Cosi, Chiara Magri, Antonio Frassoldati, Lucio Crinò, Luana Calabrò · 2023 · International Journal of Molecular Sciences
37. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma
    Zhouhua Li, Wenjun Wang, Juan Wu, Xiaoqun Ye · 2022 · Frontiers in Medicine
38. Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
    Yi-Long Lung Cancer Wu, Shun Lü, Ying Cheng, Qing Hua Zhou, Hai‐Yan Tu, Qinghua Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang et al. · 2023 · Medicine Advances
39. NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patients
    Jean-Stéphane Giraud, Anne Jouinot, Éric Pasmant, Camille Tlemsani · 2024 · npj Precision Oncology
40. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication
    Lanlan Pang, H.-Q. Zhou, Y.-X. Zhang, Weitao Zhuang, Fei Pang, L.-J. Chen, J. Liao, Yizhou Huang, T.-Q. Mao, Z.-H. Mai et al. · 2024 · ESMO Open
41. SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response
    Yuming Zhang, Dantong Sun, Weizhong Han, Zhen Fan Yang, Yongzhi Lu, Xuchen Zhang, Yongjie Wang, Chuantao Zhang, Ning Liu, Helei Hou · 2024 · FEBS Open Bio
42. Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects
    Yi‐Jing Hsiao, Min‐Shu Hsieh, Gee‐Chen Chang, Yin-Chen Hsu, Chia-Yu Wang, Yan-Ming Chen, Yi-Ling Chen, Pan‐Chyr Yang, Sung‐Liang Yu · 2025 · Cell Death and Disease
43. Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
    Huiping Qiang, Yue Wang, Yao Zhang, Jingwen Li, Lincheng Zhang, Huawei Du, Xuxinyi Ling, Shuhui Cao, Yan Zhou, Runbo Zhong et al. · 2025 · Translational Oncology
44. Bibliometric and visualized analysis of global distribution and research frontiers in tumor immune escape
    Chaihong Zhang, Lihong Chen · 2025 · Frontiers in Immunology
45. Risk scoring model for lung adenocarcinoma based on PD-L1 related signature reveals prognostic predictability and correlation with tumor immune microenvironment genes was constructed
    Meng Li-Fei, Simeng Ren, Jun Wang, Weijun Zhao, Jian Chen, Wentao Hu · 2025 · Frontiers in Immunology
46. Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment
    Hengchao Li, Di Yang, Ji Li, Yongjian Jiang, Hang He, Lie Yao, Jichun Gu, Jia-Jun Lu, Jia Tao Song, Shiqing Chen et al. · 2020 · Journal of Cancer
47. [Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy].
    Yaning Yang, Lu Yang, Yan Wang · 2021 · PubMed Central
48. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma
    Ye Li, Xinying Shi, Beibei Mao, Lingxiong Wang, Lijia Wu, Jie Li, Shunchang Jiao · 2022 · Lung Cancer
49. An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango
    Fang Hao · 2022 · Clinical & Translational Oncology
50. Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice
    Mengqi Song, Haoyue Cheng, Hao Zou, Kai Ma, Lianfang Lu, Qian Wei, Zejiang Xu, Zirui Tang, Yuanzheng Zhang, Yinan Wang et al. · 2024 · BMC Cancer
51. Significance of genetic sequencing in patients with lung adenocarcinoma with transformation to small cell lung cancer: a case report and systematic review
    Cuicui Zhang, Lin Li, Xin Guo, Peng Chen · 2020 · Translational Cancer Research
52. Oncostatin M expression and TP53 mutation status regulate tumor-infiltration of immune cells and survival outcomes in cholangiocarcinoma
    Qi Liu, Tian Lan, Yuxuan Song, Jian‐Peng Cai, Yu Xi, Wei Chen · 2020 · Aging
53. Identification and validation of a metabolism-related model and associated with tumor-infiltrating lymphocytes in p53 mutant lung adenocarcinoma patients
    Chang Ji Zheng, Liang Sun, Baosen Zhou, Aiping Wang · 2021 · Annals of Translational Medicine
54. Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
    Fanming Kong, Ziwei Wang, Dongying Liao, Jinhui Zuo, Hongxia Xie, Xiaojiang Li, Yingjie Jia · 2021 · Frontiers in Oncology
55. Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma
    Ying Fan, Qianyun Shan, Jiali Gong, Jing Qin, Hongyang Lu · 2021 · Frontiers in Molecular Biosciences
56. Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma
    Xuming Song, Qiang Chen, Jifan Wang, Qixing Mao, Wenjie Xia, Lin Xu, Feng Jiang, Gaochao Dong · 2021 · Journal of Cellular and Molecular Medicine
57. Mutation-Derived Long Noncoding RNA Signature Predicts Survival in Lung Adenocarcinoma
    Longjun Yang, Guangran Guo, Xiangyang Yu, Yingsheng Wen, Yongbin Lin, Rusi Zhang, Dechang Zhao, Zirui Huang, Gongming Wang, Yan Yan et al. · 2022 · Frontiers in Oncology
58. Molecular profiling identifies distinct subtypes across TP53 mutant tumors
    Xin Chen, Tianqi Liu, Jianqi Wu, Chen Ying Zhu, Gefei Guan, Cunyi Zou, Qing Guo, Xiaolin Ren, Chen Li, Cheng Peng et al. · 2022 · JCI Insight
59. Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
    Matthew Z. Guo, Kristen Ashley Marrone, Alexander I. Spira, Samuel Rosner · 2023 · Future Oncology
60. Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer
    Xiaoqing Luo, Shunli Peng, Sijie Ding, Qin Zeng, Rong Wang, Yueyun Ma, Shiyu Chen, Yanxia Wang, Wei Wang · 2021 · Cancer Cell International
61. Pulmonary Inflammation and KRAS Mutation in Lung Cancer
    Phouthone Keohavong, Y. Peter Di · 2021 · Advances in experimental medicine and biology
62. Comprehensive Analysis of the Immune and Prognostic Implication of MMP14 in Lung Cancer
    Chunlong Zheng, Qiang Lu, Nian Zhang, Pengyu Jing, Ji-peng Zhang, Wu-ping Wang, Gui-zhen Li · 2021 · Disease Markers
63. Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma
    Pengfei Gu, Yunjie Zeng, Weike Ma, Wei Zhang, Yu Liu, Fengli Guo, Xian-Hui Ruan, Jia-Dong Chi, Xiangqian Zheng, Ming Gao · 2022 · Frontiers in Endocrinology
64. Demographics and Clinicopathologic Profile of Pulmonary Sarcomatoid Carcinoma with Survival Analysis and Genomic Landscape
    Asad Ullah, Asim Ahmed, Abdul Qahar Khan Yasinzai, Kue Tylor Lee, Israr Khan, Bina Asif, Imran Khan, Bisma Tareen, Kaleemullah Kakar, Gul Andam et al. · 2023 · Cancers
65. Ubiquitin-Specific Protease 52 as a Prognostic Biomarker Correlates with Tumor Microenvironment and Therapy Response in Colorectal Cancer
    Jingkai Zhou, Haihang Nie, Xiaoqiang Yang, Fan Wang, Panpan Yu, Yali Yu, Yumei Ning, Jun Lai, Haizhou Wang, Qiu Zhao et al. · 2024 · Oncology
66. The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
    Ki Lui, Kwok‐Kuen Cheung, Winnie Wing Man Ng, Yanping Wang, Doreen W. H. Au, William Chi Shing Cho · 2024 · International Journal of Molecular Sciences
67. Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53
    Mingying Wu, Na Zhou, Mei Guan, Yingyi Wang, Yuzhou Wang · 2024 · Lung Cancer
68. Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer
    Shaojie Chen, Feifei Huang, Shangxiang Chen, Yinting Chen, Jiajia Li, Yaqing Li, Guoda Lian, Kaihong Huang · 2021 · Frontiers in Genetics
69. Potential Clinical Value of 5-Hydroxytryptamine Receptor 3C as a Prognostic Biomarker for Lung Cancer
    Jiun-Rung Chen, Ming‐Shyan Huang, Yi‐Chen Lee, Min-His Lin, Yi‐Fang Yang · 2021 · Journal of Oncology
70. Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
    Jie Dai, Xue Li Bai, Xuan Gao, Lirui Tang, Yu Chen, Linzi Sun, Xiaoting Wei, Caili Li, Zhonghui Qi, Yan Kong et al. · 2023 · Journal for ImmunoTherapy of Cancer
71. The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
    Sun Young Jeong, Jung Yong Hong, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Jae Yeon Jang, Youngkyung Jeon, Seung Tae Kim · 2023 · Therapeutic Advances in Gastroenterology
72. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
    Qi Wang, Zhuoran Tang, Chunyu Li, Xuefei Li, Chunxia Su · 2023 · Frontiers in Immunology
73. The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma
    Liying Yu, Na Lin, Ye Yan, Haohan Zhuang, Shumei Zou, Yingfang Song, Xiaoli Chen, Qingshui Wang · 2024 · Aging
74. East Asian patients who received immunotherapy‐based therapy associated with improved survival benefit in advanced non‐small cell lung cancer: An updated meta‐analysis
    Yueyuan Yao, Butuo Li, Yiyue Xu, Linlin Yang, Bing Zou, Linlin Wang · 2024 · Cancer Medicine
75. Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice
    Francesco Passiglia, Oriana Commendatore, Milena Vitali, Raffaele Conca · 2018 · Future Oncology
76. The Characteristic of Tumor Immune Microenvironment in Pulmonary Carcinosarcoma
    Yanhong Cen, Zhao Huang, Jiangbo Ren, Junhong Zhang, Yan Qing Gong, Conghua Xie · 2020 · Immunotherapy
77. A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations
    Takamasa Nakasuka, Kadoaki Ohashi, Hiromi Watanabe, Toshio Kubo, Shingo Matsumoto, Kōichi Goto, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura · 2021 · Lung Cancer
78. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non‐small cell lung cancer patients treated with immune checkpoint inhibitors
    Lijuan Zhang, Tongyan Zhang, Bin Shang, Yaqiong Li, Zhixin Cao, Hui Wang · 2021 · Scandinavian Journal of Immunology
79. Recent advances in lung cancer genomics: Application in targeted therapy
    Neha Pathak, Sindhura Durga Chitikela, Prabhat Singh Malik · 2021 · Advances in genetics
80. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report
    Yufeng Li, Xin-Fei Zhao, Yue Tian, Xin-Yao Xiao, Caiyun Yan, Hua Shen · 2022 · Frontiers in Genetics
81. Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma
    Ning Zhou, Quanying Tang, Haochuan Yu, Tong Li, Fan Ren, Lingling Zu, Gang Chen, Jun Chen, Song Xu · 2022 · Frontiers in Molecular Biosciences
82. Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma
    Zhimin Zeng, Yuxia Liang, Jia Shi, Lisha Xiao, Lu Tang, Yubiao Guo, Fengjia Chen, Gengpeng Lin · 2022 · Diagnostics
83. Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
    Abolarinwa Bilikis Aderonke, Ridwan Babatunde Ibrahim, Yen‐Hua Huang · 2019 · International Journal of Molecular Sciences
84. Direct KRAS inhibition: progress, challenges, and a glimpse into the future
    Dimitra Grapsa, Konstantinos Syrigos · 2020 · Expert Review of Anticancer Therapy
85. Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma
    Cong Fu, Haoran Gu, Lin Sun, Zhouyu Wang, Qin Zhang, Ningning Luo, Dongsheng Chen, Tong Hui Zhou · 2024 · Investigational New Drugs
86. If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
    Jens Köhler, Pasi Antero Janne · 2021 · International Journal of Molecular Sciences
87. Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma
    Lijuan Tang, Zhike Chen, Jian Yang, Qifan Li, Sichu Wang, Taoming Mo, Weibiao Zeng, Hao Ding, Shu Pan · 2024 · Frontiers in Immunology
88. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials
    Jinliang Wang, Wenyong Zhou, Yu Xu, Jianchun Duan, Qiaoxia Zhou, Guoqiang Wang, Leo Li, Chunwei Xu, Wenxian Wang, Shangli Cai et al. · 2024 · Science China Life Sciences
89. T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia
    Talha Badar, Keith L. Knutson, James M. Foran, Naseema Gangat, Kevin D. Pavelko, Scott H. Kaufmann, Mark Robert Litzow, Hemant S. Murthy, Davitte Cogen, Margaret Ushman et al. · 2024 · Blood Advances
90. Identification of the Immune Cell Infiltration Landscape in Pancreatic Cancer to Assist Immunotherapy
    Zizheng Wang, Wenbo Zou, Fei Wang, Gong Zhang, Kuang Chen, Minggen Hu, Rong Liu · 2021 · Future Oncology
91. Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
    Lei Xu, Wanru Li, Ting Yang, Siqi Hu, Qiong Zou, Ju Jiao, Ningyi Jiang, Yong Zhang · 2022 · Frontiers in Molecular Biosciences
92. Molecular Signatures of KRAS -Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR , ALK , STK11 , and PD-L1 Status
    Jim Wei-Chun Hsu, Joseph F Annunziata, Ethan Alexander Burns, Eric Bernicker, Randall J. Olsen, Jessica S. Thomas · 2022 · Clinical Pathology
93. Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery
    Peilin Dai, Xi Rao, Xi Zhang, Enming Qiu, Gang Wu, Yu Syuan Lin, Sitong Li, Zhou Li, Zhai Cai, Shuai Han · 2022 · Frontiers in Immunology
94. Non-Small-Cell Lung Cancer Patients Harboring TP53/KRAS Co-Mutation could Benefit from a PD-L1 Inhibitor
    Chenyue Zhang, Kai Wang, Jiamao Lin, Haiyong Wang · 2022 · Future Oncology
95. Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non–small cell lung cancer
    Geyun Chang, Weihua Li, Hua Bai, Jianchun Duan, Zhijie Wang, Xinyang Du, Ruofei Yu, Yaxi Wang, Minghao Wang, Yixiang Zhu et al. · 2022 · Thoracic Cancer
96. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients
    Chuanbing Zhao, Zhengle Zhang, Jing Tao · 2022 · Current Oncology
97. Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC
    Zemin Wang, You Ge, Han Li, Gaoqiang Fei, Shuai Wang, Pingmin Wei · 2022 · Bioscience Reports
98. Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma
    Xincheng Zhou, Bing Zou, Jian Wang, Lihong Wu, Qiang Tan, Chunyu Ji · 2022 · Frontiers in Genetics
99. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Yanxia Liu, Yuan Jiao Gao, Ying Wang, Cong Zhao, Zhiyun Zhang, Baolan Li, Tongmei Zhang · 2022 · BMC Cancer
100. Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer
     Zhenpeng Li, Xin Wang, Yi Yang, Fuyan Shi, Wenjing Zhang, Qinghua Wang, Suzhen Wang · 2022 · Cells